{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=16",
    "query": {
      "intervention": "Amino Acid",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 16003,
    "total_pages": 1601,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T00:54:29.100Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01973543",
      "title": "Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "VY-AADC01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-10",
      "completion_date": "2020-01-24",
      "has_results": false,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01973543"
    },
    {
      "nct_id": "NCT04445025",
      "title": "Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Infertility",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Elagolix 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate 3.75 MG/ML",
          "type": "DRUG"
        },
        {
          "name": "Lab work",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Colorado Center for Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 42 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-09-01",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 1,
      "location_summary": "Lone Tree, Colorado",
      "locations": [
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445025"
    },
    {
      "nct_id": "NCT00063193",
      "title": "National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "minocycline",
          "type": "DRUG"
        },
        {
          "name": "creatine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 195,
      "start_date": "2003-05",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063193"
    },
    {
      "nct_id": "NCT00505921",
      "title": "Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Campath-1H",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "BCNU",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "DRUG"
        },
        {
          "name": "Preparative Regimen for Allogenic Stem Cell Transplantation",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Low dose total body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2003-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2011-11-16",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505921"
    },
    {
      "nct_id": "NCT03071055",
      "title": "Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exudative Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab Injection [Lucentis]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Clinical Research Associates, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-10-01",
      "completion_date": "2019-06-03",
      "has_results": false,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Statesville, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071055"
    },
    {
      "nct_id": "NCT06250335",
      "title": "Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ICB-refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "Prebiotic Food-Enriched Diet",
          "type": "OTHER"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2024-03-01",
      "completion_date": "2029-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06250335"
    },
    {
      "nct_id": "NCT03629717",
      "title": "RANKL Inhibition and Breast Tissue Biomarkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Breast Cancer Prevention",
        "Mammographic Density"
      ],
      "interventions": [
        {
          "name": "Ultrasound-guided core needle biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Denosumab",
          "type": "DRUG"
        },
        {
          "name": "Blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Calcium",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "35 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2018-06-01",
      "completion_date": "2018-12-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03629717"
    },
    {
      "nct_id": "NCT04557384",
      "title": "A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-02-23",
      "completion_date": "2021-05-25",
      "has_results": true,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 4,
      "location_summary": "Fayetteville, Arkansas • Omaha, Nebraska • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557384"
    },
    {
      "nct_id": "NCT02435433",
      "title": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 399,
      "start_date": "2015-07-20",
      "completion_date": "2021-11-19",
      "has_results": true,
      "last_update_posted_date": "2023-01-20",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 8,
      "location_summary": "Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02435433"
    },
    {
      "nct_id": "NCT00160355",
      "title": "Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wiskott-Aldrich Syndrome"
      ],
      "interventions": [
        {
          "name": "Hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Miltenyi CliniMACS selection system",
          "type": "DEVICE"
        },
        {
          "name": "Fludarabine, Melphalan, Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "Up to 18 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2005-05",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-11-19T00:54:29.100Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00160355"
    }
  ]
}